Rising Lung Cancer Burden Attributable to High Fasting Plasma Glucose in Women Aged ≥50 Years: Age-, SDI-, and BRICS-Specific Patterns from GBD 1990-2021.
{"title":"Rising Lung Cancer Burden Attributable to High Fasting Plasma Glucose in Women Aged ≥50 Years: Age-, SDI-, and BRICS-Specific Patterns from GBD 1990-2021.","authors":"Lili Lin, Xiaoqin Huang, Bijun Li, Jinjian Li, Hui Chen","doi":"10.1159/000552661","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>We quantified trends and heterogeneity in lung cancer burden attributable to high fasting plasma glucose (HFPG) among women aged ≥50 years (used as a population-level proxy for postmenopausal status) globally and across BRICS countries from 1990 to 2021.</p><p><strong>Methods: </strong>HFPG-attributable lung cancer deaths and disability-adjusted life years (DALYs) for women aged ≥50 years were obtained from Global Burden of Disease 1990-2021. Burden was summarized as numbers and age-standardized rates (ASR) per 100,000, stratified by age, Socio-demographic Index (SDI) quintile, and country. Trends were assessed using estimated annual percentage change (EAPC) from log-linear regression.</p><p><strong>Results: </strong>Global HFPG-attributable deaths and DALYs increased markedly from 1990 to 2021, with rising ASR (global EAPC 1.21; 95% CI, 1.11-1.31). A strong age gradient was observed; EAPC increased from 0.53% (50-54 years) to 3.65% (≥95 years). In 2021, the DALYs ASR peaked in the 75-79 years group (59.38 per 100,000). High-SDI settings consistently had the highest ASR and increasing burden. In BRICS, the ASR of DALYs increased in all five countries with substantial heterogeneity; India showed the fastest increase (EAPC 3.05; 95% CI, 2.91-3.19), followed by South Africa (2.82; 2.64-3.00), and Brazil (2.36; 2.31-2.42), while China showed the smallest increase (0.87; 0.70-1.03).</p><p><strong>Conclusion: </strong>HFPG-attributable lung cancer burden in women aged ≥50 years rose substantially from 1990 to 2021, with disproportionate growth in older ages and clear SDI/BRICS differences, supporting integrated metabolic prevention within cancer control and healthy aging strategies.</p>","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"1-10"},"PeriodicalIF":1.9000,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000552661","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: We quantified trends and heterogeneity in lung cancer burden attributable to high fasting plasma glucose (HFPG) among women aged ≥50 years (used as a population-level proxy for postmenopausal status) globally and across BRICS countries from 1990 to 2021.
Methods: HFPG-attributable lung cancer deaths and disability-adjusted life years (DALYs) for women aged ≥50 years were obtained from Global Burden of Disease 1990-2021. Burden was summarized as numbers and age-standardized rates (ASR) per 100,000, stratified by age, Socio-demographic Index (SDI) quintile, and country. Trends were assessed using estimated annual percentage change (EAPC) from log-linear regression.
Results: Global HFPG-attributable deaths and DALYs increased markedly from 1990 to 2021, with rising ASR (global EAPC 1.21; 95% CI, 1.11-1.31). A strong age gradient was observed; EAPC increased from 0.53% (50-54 years) to 3.65% (≥95 years). In 2021, the DALYs ASR peaked in the 75-79 years group (59.38 per 100,000). High-SDI settings consistently had the highest ASR and increasing burden. In BRICS, the ASR of DALYs increased in all five countries with substantial heterogeneity; India showed the fastest increase (EAPC 3.05; 95% CI, 2.91-3.19), followed by South Africa (2.82; 2.64-3.00), and Brazil (2.36; 2.31-2.42), while China showed the smallest increase (0.87; 0.70-1.03).
Conclusion: HFPG-attributable lung cancer burden in women aged ≥50 years rose substantially from 1990 to 2021, with disproportionate growth in older ages and clear SDI/BRICS differences, supporting integrated metabolic prevention within cancer control and healthy aging strategies.
期刊介绍：
Although laboratory and clinical cancer research need to be closely linked, observations at the basic level often remain removed from medical applications. This journal works to accelerate the translation of experimental results into the clinic, and back again into the laboratory for further investigation. The fundamental purpose of this effort is to advance clinically-relevant knowledge of cancer, and improve the outcome of prevention, diagnosis and treatment of malignant disease. The journal publishes significant clinical studies from cancer programs around the world, along with important translational laboratory findings, mini-reviews (invited and submitted) and in-depth discussions of evolving and controversial topics in the oncology arena. A unique feature of the journal is a new section which focuses on rapid peer-review and subsequent publication of short reports of phase 1 and phase 2 clinical cancer trials, with a goal of insuring that high-quality clinical cancer research quickly enters the public domain, regardless of the trial’s ultimate conclusions regarding efficacy or toxicity.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
